



26th August 2016

BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	18448.41	-0.18%	+5.87%
S&P 500	2172.47	-0.14%	+6.29%
Nasdaq	5212.2	-0.11%	+4.09%
Nikkei	16360.71	-1.18%	-13.02%
Stoxx 600	342.02	-0.84%	-6.50%
CAC 40	4406.61	-0.65%	-4.97%
Oil /Gold			
Crude WTI	46.93	+1.21%	+26.16%
Gold (once)	1323.07	-0.33%	+24.54%
Currencies/Rates			
EUR/USD	1.1282	+0.29%	+3.86%
EUR/CHF	1.09175	+0.30%	+0.40%
German 10 years	-0.137	-8.73%	-121.66%
French 10 years	0.165	+10.04%	-83.17%

Economic releases :

Date	
26th-Aug	JP - CPI (-0.4% A as Exp.) GB - GDP 2Q (E +2.2% y/y) DE - GfK consumer confidence Survey (10E) FR - GDP 2Q (1.4% E) US - GDP annualized (1.1% E) US - U. of Michigan Confidence Aug. (90.8E)

Upcoming BG events :

Date	
1st-Sept	L'OREAL (BG Paris roadshow with CFO)
8th-Sept	ACCOR (BG Roadshow with CFO)
13th-Sept	Thematic Breakfast with ARCEP
14th-Sept	SAINT GOBAIN (BG Luxembourg roadshow)
22nd-Sept	Thematic Lunch with HC specialist
30th-Sept	Thematic Breakfast with Vimpelcom

Recent reports :

Date	
24th-Aug	AMS Catching the ball when it bounces - all a question of timing
26th-Jul	NICOX Don't turn a blind eye to opportunities
21st-Jul	SEMICONDUCTORS : Looking for lost growth
13th-Jul	Oncology is an increased focus
12th-Jul	DANONE No redemption
1st-Jul	UBISOFT Same player shoot again?

List of our Reco & Fair Value : Please click here to download



GEMALTO

NEUTRAL, Fair Value EUR62 (+7%)

Mixed H1 earnings, unattractive momentum as long as the FY17 guidance is maintained

Gemalto posted mixed H1 earnings results, with sales and profit from operations (PFO) roughly in line with our estimates and those of the consensus but attributable net profit 20% below expectations. Management has confirmed its vague 2016 guidance (+1.5% gross margin, accelerating its PFO expansion towards its 2017 objectives). We expect momentum to be unattractive as long as management maintains its 2017 PFO target which is out of reach. Conf. call today at 3pm (Paris time).

U-BLOX

BUY, Fair Value CHF265 (+11%)

H1 results below expectations but FY16 EBIT guidance and long term view unchanged

u-blox has reported H1 2016 results slightly below consensus expectations, although it is maintaining its FY16 operating result guidance. H1 2016 sales came out at CHF180m, up 1.9% on a sequential basis and up 11% year on year. This was below consensus forecasts for CHF191m. H1 2016 net result stood at CHF18.7m, also below consensus expectations of CHF21.6 mainly due to higher financial costs than expected in H1. Beyond H1, the group's comments regarding mid and long term growth are reassuring and despite reducing its FY16 sales estimate, it has made no change to its FY16 operating profit figure. Overall, we maintain our view on the case and reiterate our Buy recommendation.

FOOD INDUSTRY

Q2 earnings season review

The earnings season was positive for our coverage. Organic sales growth remained modest (4% on average in Q2) due to the weak pricing environment and macro uncertainties in emerging countries, especially China. But profitability improved. Nestlé should post an acceleration in organic sales growth in H2 vs H1 and stronger improvement in profitability, while Danone and Unilever are expected to face a deterioration. We still favour the Swiss group (Buy; Fair Value: CHF84). We think that 1/ going forward it will better use its size to optimise its cost base and working capital and 2/ the arrival of the new CEO in 2017 should trigger a more efficient policy for the group's cash.

In brief...

ADOCIA, BC PDGF fails in India and its development is discontinued as a consequence

SAP, Acquiring Altiscale for over USD125m?

TMT

Gemalto

Price EUR58.21

Mixed H1 earnings, unattractive momentum as long as the FY17 guidance is maintained

Fair Value EUR62 (+7%)

NEUTRAL

Bloomberg	GTO.FP
Reuters	GTO.PA
12-month High / Low (EUR)	73.9 / 49.8
Market Cap (EUR)	5,233
Ev (BG Estimates) (EUR)	5,313
Avg. 6m daily volume (000)	380.1
3y EPS CAGR	23.8%

Gemalto posted mixed H1 earnings results, with sales and profit from operations (PFO) roughly in line with our estimates and those of the consensus but attributable net profit 20% below expectations. Management has confirmed its vague 2016 guidance (+1.5% gross margin, accelerating its PFO expansion towards its 2017 objectives). We expect momentum to be unattractive as long as management maintains its 2017 PFO target which is out of reach. Conf. call today at 3pm (Paris time).

ANALYSIS

Mixed H1 earnings: revenue came in at EUR1,495.2m (-0.3% Y/Y; +0.5 lfl: Q1 -2.5% and Q2 +3%) vs. BG EUR1,480m and consensus EUR1,491m. Sales broke down into Payment & Identity EUR937m (+14% lfl: Q1 +13% and Q2 +11%), Mobile EUR552m (-13% lfl incl. SIM at -26%: Q1 -20% incl. SIM at -34%, and Q2 -5% incl. SIM at -16% i.e. end of the negative Softcard comparison base but still a double digit decline, lower demand in Latam and Asia, and no software upgrade), and Patents & Others EUR1m (-92% lfl: Q1 -29% and Q2 -94%). **The gross margin was 39.0%** (vs BG: 39.1%; consensus: 39.3%), driven mainly by the Payment & Identity segment and in particular the Payment and Enterprise businesses. **PFO reached EUR171.7m, up 90bp to a margin of 11.5%** (vs BG: EUR170m, i.e. margin of 11.5%; cons.: EUR169m, i.e. margin of 11.3%) breaking down into P&I 12.6% (+340bps), Mobile 10.6% (-50bp) and Patents & Others -EUR5.4m (vs. a margin of 63% last year). After stock-based compensation, Gemalto generated a **current EBIT of EUR151m (margin of 10.1%)** vs our EUR150.3m (margin of 10.2%). Note that the group booked EUR14.1m in non-current operating charges during the period (from IT and facilities integration costs of SafeNet and Trüb and from the implementation of a new ERP). **IFRS attributable net profit came to only EUR57.7m, i.e. margin of 3.9%** (vs BG: EUR72.7m, i.e. margin of 4.9%; cons.: EUR72m, i.e. margin of 4.8%). The main difference with our expectations was the non-recurring loss relating to associates (impairment of -EUR16.9m on Goldpac Group in China). **The company generated a FCF of EUR64m (FCF/current EBIT of 42%) and a net debt of EUR334m (gearing of 13%).**

Management has confirmed its vague 2016 guidance: "to generate a +1.5% gross margin increase, accelerating its profit from operations expansion towards its 2017 objectives" (i.e. above the 10.4% growth reported last year).

What are our current 2016 estimates? We have a FY16 revenue of EUR3,243.8m (+3.0% lfl), PFO of EUR483.3m (margin of 14.9%), current EBIT of EUR438.9m (margin of 13.5%) and attributable net profit of EUR288.5m (margin of 8.9%).

What about the FY17 PFO target? Philippe Vallée (COO, and new CEO as of 1st September) will have to take on guidance for over EUR660m in PFO for next year. This target looks increasingly tight from one publication to the next since it suggests a strong acceleration in the following two years, namely a 2015/17 CAGR of at least +25%. Even with the dynamics registered in payment, M2M, e-government and cybersecurity, the business lost in the SIM segment (very profitable) has a poor momentum. **We have a FY17e PFO at EUR580m, i.e. more than 12% below the guidance.**

VALUATION

Waiting for the conference call today at 3pm, we maintain our Neutral rating and FV of EUR62 (average between a SOTP, a DCF, and 3-year historical multiples).

We do not see a positive risk/reward on the stock. The current year is very back-end loaded, visibility is poor, Olivier Piou will have to ensure a smooth succession with Philippe Vallée (effective as of 1st September), we still see too many risks in the SIM and related services business, and we do not see a potential acquisition of Morpho as positive from a financial point of view (it would be expensive and not easy to integrate given its size and its profitability level: revenue of -EUR1.6bn and EBIT margin of 6%). **We expect momentum to be unattractive as long as management maintains its 2017 PFO target which is out of reach.**

NEXT CATALYSTS

Gemalto's Q3 revenue: on 28th October (before trading). [Click here to download](#)

	1 M	3 M	6 M	31/12/15
Absolute perf.	-1.5%	4.9%	5.7%	5.3%
Softw. & Comp.	1.6%	4.9%	11.2%	3.8%
DJ Stoxx 600	0.3%	-1.9%	4.7%	-6.5%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	3,122	3,244	3,406	3,610
% change		3.9%	5.0%	6.0%
EBITDA	345	513	609	677
EBIT	313.3	438.9	529.0	588.5
% change		40.1%	20.5%	11.3%
Net income	226.3	329.7	396.7	432.8
% change		45.7%	20.3%	9.1%

	2015	2016e	2017e	2018e
Operating margin	10.0	13.5	15.5	16.3
Net margin	4.2	8.9	10.5	11.1
ROE	5.4	10.5	11.7	11.8
ROCE	7.1	10.0	12.1	13.4
Gearing	13.4	2.9	-7.5	-16.7

(EUR)	2015	2016e	2017e	2018e
EPS	2.53	3.66	4.41	4.81
% change	-	44.6%	20.3%	9.1%
P/E	23.0x	15.9x	13.2x	12.1x
FCF yield (%)	3.3%	5.9%	7.2%	8.1%
Dividends (EUR)	0.47	0.51	0.55	0.59
Div yield (%)	0.8%	0.9%	0.9%	1.0%
EV/Sales	1.8x	1.6x	1.5x	1.3x
EV/EBITDA	16.1x	10.4x	8.2x	6.9x
EV/EBIT	17.8x	12.1x	9.5x	7.9x



Analyst :
Richard-Maxime Beaudoux
33(0) 1.56.68.75.61
rmbeaudoux@bryangarnier.com

Sector Team :
Thomas Coudry
Gregory Ramirez
Dorian Terral

TMT

u-blox

Price CHF238.30

H1 results below expectations but FY16 EBIT guidance and long term view unchanged

Fair Value CHF265 (+11%)

BUY

Bloomberg	UBXN.SW
Reuters	UBXN.S
12-month High / Low (CHF)	246.4 / 164.0
Market Cap (CHFm)	1,622
Ev (BG Estimates) (CHFm)	1,551
Avg. 6m daily volume (000)	21.30
3y EPS CAGR	29.5%

	1 M	3 M	6 M	31/12/15
Absolute perf.	1.2%	18.7%	23.5%	11.1%
Semiconductors	0.6%	20.3%	31.7%	18.7%
DJ Stoxx 600	0.3%	-1.9%	4.7%	-6.5%

YEnd Dec. (CHFm)	2015	2016e	2017e	2018e
Sales	338.3	404.5	500.6	635.1
% change		19.6%	23.8%	26.9%
EBITDA	76.0	89.0	110	138
EBIT	51.3	59.9	73.1	98.4
% change		16.7%	22.1%	34.7%
Net income	37.1	46.7	58.6	80.5
% change		25.9%	25.4%	37.5%

	2015	2016e	2017e	2018e
Operating margin	15.2	14.8	14.6	15.5
Net margin	11.0	11.5	11.7	12.7
ROE	14.9	16.5	18.0	21.1
ROCE	21.8	21.8	23.0	25.3
Gearing	-26.1	-24.9	-23.2	-20.0

(CHF)	2015	2016e	2017e	2018e
EPS	5.45	6.86	8.60	11.82
% change	-	25.9%	25.4%	37.5%
P/E	43.7x	34.7x	27.7x	20.2x
FCF yield (%)	2.0%	1.1%	1.2%	1.3%
Dividends (CHF)	1.57	1.71	2.15	2.96
Div yield (%)	0.7%	0.7%	0.9%	1.2%
EV/Sales	4.6x	3.8x	3.1x	2.4x
EV/EBITDA	20.5x	17.4x	14.1x	11.2x
EV/EBIT	30.4x	25.9x	21.2x	15.7x

u-blox has reported H1 2016 results slightly below consensus expectations, although it is maintaining its FY16 operating result guidance. H1 2016 sales came out at CHF180m, up 1.9% on a sequential basis and up 11% year on year. This was below consensus forecasts for CHF191m. H1 2016 net result stood at CHF18.7m, also below consensus expectations of CHF21.6 mainly due to higher financial costs than expected in H1. Beyond H1, the group's comments regarding mid and long term growth are reassuring and despite reducing its FY16 sales estimate, it has made no change to its FY16 operating profit figure. Overall, we maintain our view on the case and reiterate our Buy recommendation.

ANALYSIS

- **u-blox has reported H1 results below consensus expectations.** The company reported H1 sales of CHF180m, up 11% yoy (up 1.9% seq.), below consensus expectations at CHF191m (BG ests. CHF194m). The gross margin increased by 100bp compared to the first half of 2015 and stood at 45.9% in H1 2016 (vs. 44.9% in H1 2015). Operating result came in at CHF27.8m or a 15.5% margin compared with the 14.8% achieved a year before. The slight improvement was mainly due to higher volumes. Net profit of CHF18.5m was also below consensus expectations at CHF21.6m. We understand that the net profit defers from expectations due to higher financial expenses than expected by the consensus. Finally, cash generation remained strong with net cash generated from operating activities of CHF26.3m (up 23.6% yoy).
- **Both divisions "Positioning and Wireless products" and "Wireless services" showed a good performance.** Revenue of the main division "Positioning and Wireless products" was CHF180m for the first half of 2016, i.e. 11% above the H1 2015 level. In addition, revenue for "wireless services" was CHF15.1m (including intra-group revenue) or 17.8% above the level achieved a year ago.
- **FY16 Guidance fine-tuned but with no impact on EBIT forecasts, LT view unchanged.** For the current year, u-blox was previously targeting revenues in the range of CHF395-405m or growth between 16.7% and 19.7% compared to FY15 sales. Today, the group has adjusted its expectations and now foresees FY16 sales in the range of CHF375-385m. The group nevertheless added that it remains confident for the future given supportive u-blox product traction and strong customer pipelines. U-blox also stated that numerous customers are scheduling ramp-ups for major projects in the short and long term. **Overall, despite adjusting its top-line expectations, the group is maintaining its EBIT guidance of CHF56-60m in the context of an improving margin thanks to a positive change in the mix.**

H1 2016 Actual vs. estimates

[CHFm]	BG ests. 1H16e	Consensus 1H16e	1H16 Actual	Actual vs. Cons.
Net revenue	194	191	180	-6.1%
% change (seq)	10.0%	8.5%	1.9%	-663bp
% change (yoy)	19.9%	18.2%	11.0%	-723bp
Gross Margin	44.8%	45.1%	45.0%	-10bp
Adj. EBIT	28.7	27.9	27.8	-0.4%
% of revenue	14.8%	14.6%	15.5%	89bp
Adj. Net result	22.41	21.6	18.7	-13.4%

Sources: Bloomberg; Bryan, Garnier & Co ests.


FY16 Guidance vs. estimates

[CHFm]	BG ests. 2016e	Consensus 2016e	2H16 Guidance	Guid. vs. Cons.
Net revenue	405	404	375 to 385	-5.9%
% change (seq)	+19.6%	+19.4%	10.8% to 13.8%	
Adj. EBIT	59.9	60.0	56 to 60	-3.3%
% of revenue	14.8%	14.9%		

Sources: Bloomberg; Bryan, Garnier & Co ests.

VALUATION

- We are making no change to our estimates at this point. Based on our forecasts, u-blox' shares trade at a 2016e P/E ratio of 34.7x and a 2016e PEG ratio of 1.2x.



NEXT CATALYSTS

- 23rd September 2016: Investor and Analyst Day

[Click here to download](#)



Analyst :
Dorian Terral
33(0) 1.56.68.75.92
dterral@bryangarnier.com

Sector Team :
Richard-Maxime Beaudoux
Thomas Coudry
Gregory Ramirez

Sector View

Food industry

Q2 earnings season review

	1 M	3 M	6 M	31/12/15
Food & Bev.	-1.3%	1.3%	5.6%	-0.2%
DJ Stoxx 600	0.3%	-1.9%	4.7%	-6.5%

*Stoxx Sector Indices

Companies covered

DANONE	NEUTRAL	EUR67
Last Price	EUR68.22	Market Cap. EUR44,745m
NESTLE	BUY	CHF84
Last Price	CHF77.8	Market Cap. CHF242,126
UNILEVER	NEUTRAL	EUR43
Last Price	EUR40.855	Market Cap. EUR117,119
UNILEVER Plc	NEUTRAL	3590p
Last Price	3526.5p	Market Cap. GBP45,261m

The earnings season was positive for our coverage. Organic sales growth remained modest (4% on average in Q2) due to the weak pricing environment and macro uncertainties in emerging countries, especially China. But profitability improved. Nestlé should post an acceleration in organic sales growth in H2 vs H1 and stronger improvement in profitability, while Danone and Unilever are expected to face a deterioration. We still favour the Swiss group (Buy; Fair Value: CHF84). We think that 1/ going forward it will better use its size to optimise its cost base and working capital and 2/ the arrival of the new CEO in 2017 should trigger a more efficient policy for the group's cash.

ANALYSIS

- Q2 sales figures showed: continued pressure on prices...with Nestlé suffering the most.** The group's pricing effect continued to slow, rising just 0.4% in Q2 after +0.9% in Q1, reflecting the deflationary environment in a number of developed markets, the lack of rebound in commodity prices and the tough comparison base (price increases in Latam and Eastern Europe last year). **Unilever reiterated that there is unlikely to be any improvement in pricing in 2016 vs 2015.** The company expects growth of around 2%. This is despite a good performance in Q2. The price effect picked up to 2.8% after +2% in Q1. **Danone said that excluding in Brazil it did not take any price increases in Q2...and deterioration in China. The food & beverage market has significantly slowed and is now flat.** Danone (the country accounts for 7% of its group's sales) said that the destocking at Mizone was not over at the end of H1 and the non-alcoholic beverages segment is now flat to up low single digit. When it released its 2015 results, it had indicated growth between 5% and 10%. Nestlé (which generates 8% of its sales in China) reported that the trend at Yinlu remains negative and is not expected to improve before 2017. These two groups are facing a **deterioration in the Chinese infant nutrition market** affected by a combination of low milk prices, a tough competitive environment and regulatory changes. According to Danone, this market is now growing between 3% and 5%, compared with double digit growth in the past.
- But profitability improved. All our groups beat consensus expectations for EBIT margin:** Nestlé +30bp vs consensus +20bp, Danone +125bp vs consensus +80bp, and Unilever +50bp vs consensus +30bp. **This was mainly the result of the low input cost environment although they also benefited from margin-accretive innovations.** On this topic, it is interesting to mention that Unilever increased margin in its Home Care division by 250bp to 9.8% and is now very close to reaching its medium term target of 10%. **Efforts to optimise cost bases also helped.**
- What about the H2 outlook? Nestlé's organic sales growth should accelerate** (organic sales expected to rise 4.6% after +3.5% in H1) thanks to: 1/ a pricing recovery driven by price increases in Brazil, Russia, Turkey, Ukraine and the UK..., 2/ easy comps as H2 2015 was impacted by a rebate adjustment on skin health products in the US and the Maggi noodles recall in India and 3/ the deconsolidation of the poorly performing ice cream business in Europe with the closing of the Froneri transaction at the end of the summer. **In contrast, we expect a slowdown at Unilever and Danone.** The Anglo-Dutch group said that organic sales growth momentum in the second part of the year (our estimate: +3.4% after +4.7% in H1) should be penalised by tough comps (+5.3% in H2 2015 after +2.9% in H1) and a deterioration in the business environment due to political uncertainty (Brexit referendum, presidential impeachment in Brazil, coup attempt in Turkey) and the economic slowdown in LATAM and Europe. In H2 we anticipate Danone's sales to increase 2.9% organically, decelerating vs H1 (+3.8%) due to tougher comps for yoghurts, poor performance of Mizone and regulatory issues in China. **The EBIT margin improvement in H2 should be above H1 for Nestlé** (easy comps for the AOA and Other Businesses divisions) **and below H1 for Unilever** (increase in marketing expenses and restructuring charges) **and Danone** (less favourable comparison base for input costs and no positive one-offs).

VALUATION/ NEXT CATALYSTS

- At yesterday's share price, Nestlé's stock is trading at 22.0x P/E 2016e vs 22.0x for Unilever and 22.4x for Danone / Q3 2016 sales in October: Unilever on 13th, Danone on 18th and Nestlé on 20th. [Click here to download](#)



Analyst :
Virginie Roumage
33(0) 1.56.68.75.22
vroumage@bryangarnier.com

Sector Team :
Nikolaas Faes
Loic Morvan
Antoine Parison
Cédric Rossi

Healthcare

Adocia

Price EUR56.40

BC PDGF fails in India and its development is discontinued as a consequence

Fair Value EUR90 vs. EUR100 (+60%)

BUY

Bloomberg	ADOC.FP
Reuters	ADOC.FR
12-month High / Low (EUR)	89.3 / 44.4
Market Cap (EUR)	386
Avg. 6m daily volume (000)	25.60

	1 M	3 M	6 M	31/12/15
Absolute perf.	10.6%	2.2%	11.2%	-23.0%
Healthcare	-5.1%	-2.3%	3.3%	-8.3%
DJ Stoxx 600	0.3%	-1.9%	4.7%	-6.5%

	2015	2016e	2017e	2018e
P/E	30.7x	74.3x	NS	32.9x
Div yield (%)	NM	NM	NM	NM

ANALYSIS

- Adocia announced yesterday after market close that it would not pursue the development of its BC PDGF product in wound healing for DFU (diabetic foot ulcer) after the Indian phase III trial failed to show any benefit over placebo. Although there are obvious potential biases in the way the trial was conducted in India (including a major intra-variability of results from one recruiting centre to another) and an unprecedented placebo effect in this setting, Adocia has decided to stop all further development of the drug.
- Adocia has always said that the Indian phase III trial would be used as a base for the design of new trials in Europe and in the US. The risk of losing time (an estimated 3 to 4 years) and money (EUR15 to 20m) has become increasingly significant with this failure in India, without a reasonably clear view on the outcome. As such, Adocia will focus further on diabetes.

VALUATION

- Although this project was somewhat less strategically aligned than the others to Adocia's core competency in diabetes, the investment behind it was significant and its phase III status gave it some visibility within the pipeline. Rationale was therefore high enough to support a PoS of 60% and we now have to remove the drug from our model.
- We have also taken this opportunity to update our model and factor in Lilly's announcement in July that BC lispro's filing would move from end-2016 to 2017 (to be ready on the manufacturing front).
- Altogether, the two elements have a negative influence of EUR10 on our FV.

NEXT CATALYSTS

- 12-16th September 2016: EASD meeting – potential press release by Adocia

[Click here to download](#)

Eric Le Berrigaud, eleberrigaud@bryangarnier.com

TMT

SAP

Price EUR77.50

Acquiring Altiscale for over USD125m?

Fair Value EUR75 (-3%)

NEUTRAL

Bloomberg	SAP GR
Reuters	SAPG.DE
12-month High / Low (EUR)	78.9 / 55.9
Market Cap (EURm)	95,209
Avg. 6m daily volume (000)	2,481

	1 M	3 M	6 M	31/12/15
Absolute perf. Softw.& Comp.	0.5%	7.5%	10.9%	5.6%
SVS	1.6%	4.9%	11.2%	3.8%
DJ Stoxx 600	0.3%	-1.9%	4.7%	-6.5%

	2015	2016e	2017e	2018e
P/E	20.5x	20.0x	17.6x	16.5x
Div yield (%)	1.5%	1.5%	1.7%	1.8%

ANALYSIS

- Yesterday the website VentureBeat reported SAP was acquiring Altiscale for over USD125m. Founded in 2012 and based in California, Altiscale offers a cloud version of the Hadoop open source software for storing, processing and analysing large amounts of data. It also provides a cloud version of Apache Spark, a faster alternative to Hadoop, as well as BI tools to access data from Hadoop and Spark clusters.
- - This is the kind of "bolt-on" acquisitions we expect from SAP for the next two years. Altiscale would allow SAP to save time and money on the development of products based on Hadoop and Spark. According to VentureBeat, the deal, which is expected to be announced in the next few weeks, would be valued for 3-4x the amount invested by VCs in the company.

VALUATION

- SAP's shares are trading at est. 14.8x 2016 and 13.4x 2017 EV/EBIT multiples.

NEXT CATALYSTS

- Q3 2016 results on 21st October before markets open.

[Click here to download](#)

Gregory Ramirez, gramirez@bryangarnier.com

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55.3%

NEUTRAL ratings 33.3%

SELL ratings 11.3%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities	Xavier Caroen		33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
	Pierre-Antoine Chazal		33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance	Olivier Pauchaut <i>(Head of Research)</i>		33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services	Bruno de La Rochebrochard		33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/ Infrastructures Building Materials	Eric Lemarié		33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Marketing	Sophie Braincourt		33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager	Eric Monnier		33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich	New Delhi
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11	The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062
Authorised and regulated by the Financial Conduct Authority (FCA) and Financial Conduct Authority (FCA) the Autorité de Contrôle prudentiel et de résolution (ACPR)	Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudentiel et de résolution (ACPR)			Geneva rue de Grenus 7 CP 2113 Geneve 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 Regulated by the FINMA



BRYAN, GARNIER & Co

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MiFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....